Atypical Mycobacterium Infection Clinical Trial
Official title:
Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections
This study will test the safety and effectiveness of a drug called interleukin-12 (IL-12) in
fighting severe infectious (other than tuberculosis) caused by a group of bacteria called
mycobacteria. IL-12 is similar to a substance the body produces naturally to strengthen
immune function (infection-fighting ability). It works by stimulating white blood cells to
increase production of a chemical called interferon gamma, which can improve or cure
mycobacterial infections in some patients.
In previous studies, IL-12 has improved immune function against mycobacteria in test tube
experiments and in mice. A recent study of three patients with mycobacterial infections
treated with the drug showed encouraging results. The drug has also been studied more
extensively in patients with cancer, HIV infection and hepatitis C.
Patients in this study will receive IL-12 injections under the skin twice a week for one
year. They will be taught how to self-administer the drug, but a home care nurse or a
physician may also give the injections. The drug dosage will be increased each week to
determine the safest and most effective dose for fighting this infection. If intolerable
side effects develop at a certain dose, the previous dose level will be used for the next
injection. That dose will then be used for the rest of the study, unless unacceptable side
effects develop at that level, in which case the dose will again be lowered. Patients will
receive an antibiotic against mycobacteria.
Physical examinations and blood and urine tests will be done once a month for at least the
first year and then every 3 months the following year to evaluate kidney, liver, and immune
function. The first evaluation-at the start of the study-is done on an inpatient basis.
| Status | Completed |
| Enrollment | 10 |
| Est. completion date | July 2003 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | N/A and older |
| Eligibility |
Severe disseminated or pulmonary nontuberculous mycobacterial infection refractory to the
best tolerated conventional therapy in addition to IFN gamma delivered for at least 3
months. This infection must have been proven by culture at some point during the illness.
At the time of enrollment, patients will be eligible if they have negative cultures but
histopathologic, examinable, or radiographic evidence of ongoing infection. In vitro responsiveness to IL-12 as demonstrated by augmentation of peripheral blood mononuclear cell (PBMC) phytohemagglutinin (PHA) induced IFN gamma production. Women of childbearing age must have a negative pregnancy test (urine or serum) at the time of starting the study and agree to take measures to avoid pregnancy throughout the study while receiving IL-12. Males will be advised that the effects of IL-12 on sperm are not well-known, and they should avoid conception during the study period. Age 18 years or over. Adequate hematopoietic, renal and hepatic function, defined as: Absolute neutrophil count greater than or equal to 1000/microL (G-CSF permitted); Hemoglobin greater than or equal to 9 g/dl (transfusion or erythropoietin permitted); Platelet count greater than or equal to 100,000/microL; Creatinine less than or equal to 1.5 X upper limit of normal; Bilirubin less than or equal to 1.5 X upper limit of normal; AST/SGOT less than or equal to 2.5 X upper limit of normal; ALT/SGPT less than or equal to 2.5 X upper limit of normal; Calculated Creatinine Clearance greater than 60 mL/min. Karnofsky Performance Status index greater than or equal to 70. Written signed informed consent. No HIV infection. No active malignancy. No symptomatic cardiac disease or ongoing treatment for same. No active seizure disorder or ongoing treatment for same. No pregnancy or lactation. No surgery during the two weeks prior to the start of IL-12. No concurrent use of systematic corticosteroids, except for physiologic replacement. No exposure to any investigational drug within four weeks prior to the start of dosing. No gastrointestinal bleeding or uncontrolled peptic ulcer disease. No history of inflammatory bowel disease or autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus. No other major illness which, in the investigator's judgement, will substantially increase the risk associated with the patient's participation in this study. |
Endpoint Classification: Safety Study, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | National Institute of Allergy and Infectious Diseases (NIAID) | Bethesda | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, Drysdale P, Jouanguy E, Döffinger R, Bernaudin F, Jeppsson O, Gollob JA, Meinl E, Segal AW, Fischer A, Kumararatne D, Casanova JL. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998 May 29;280(5368):1432-5. — View Citation
Altare F, Lammas D, Revy P, Jouanguy E, Döffinger R, Lamhamedi S, Drysdale P, Scheel-Toellner D, Girdlestone J, Darbyshire P, Wadhwa M, Dockrell H, Salmon M, Fischer A, Durandy A, Casanova JL, Kumararatne DS. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection. J Clin Invest. 1998 Dec 15;102(12):2035-40. — View Citation
Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospísil M, Young HA, Wolf SF, Young D, Clark SC, Trinchieri G. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med. 1991 Apr 1;173(4):869-79. — View Citation
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00004296 -
Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients
|
N/A |